## Human HLA-A\*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein

## κλιτυς

Description	
Source	Recombinant Human LMP2(HLA-A*11:01) Protein is expressed from HEK293 with His tag and Avi tag at the C- Terminus.
	It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and SSCSSCPLTK peptide.
Accession	AAV53343.1(HLA-A*11:01)&P61769(B2M)&SSCSSCPLTK
Molecular Weight	The protein has a predicted MW of 50.4 kDa. Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC
Formulation and Storage	
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background	
	The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.



Cat. No.

MHC-HM410



SEC-HPLC



Human HLA-A\*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

The purity of Human HLA-A\*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer is greater than 95% as determined by SEC-HPLC.